Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OragenicsOGEN +1.23%30 3-Year EBITDA Growth Rate is 72.80% as of Mar. 2026, which is 128% above its 10-year median of 31.90. GuruFocus rates OGEN with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 1,136 Biotechnology companies, Oragenics ranks better than 94.19% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 72.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 58.90% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 44.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Oragenics was 72.80% per year. The lowest was 1.80% per year. And the median was 31.90% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Oragenics 3-Year EBITDA Growth Rate Related Terms
OGEN vs CMND, SLXN, GRI: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Oragenics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oragenics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oragenics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Oragenics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 72.80% mean?
Oragenics (OGEN) has a 3-Year EBITDA Growth Rate of 72.80% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Oragenics and its competitors. This is 128% above median its historical median of 31.90. Over the past decade, Oragenics' 3-Year EBITDA Growth Rate has ranged from 1.80 to 72.80. According to the industry distribution chart, Oragenics ranks #66 out of 1136 companies in the Biotechnology industry, placing it in the top 5.8%.
Is Oragenics' 3-Year EBITDA Growth Rate too high?
Oragenics' current 3-Year EBITDA Growth Rate of 72.80% is 128% above median its 10-year median of 31.90. Over the past 10 years, this metric has ranged from a low of 1.80 to a high of 72.80. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.95. Oragenics' value of 72.80% is 387% above this industry median. Based on the distribution chart, Oragenics ranks #66 out of 1136 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Oragenics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Oragenics' 3-Year EBITDA Growth Rate compare to CMND and SLXN?
According to the Biotechnology industry distribution chart, Oragenics ranks #66 out of 1136 companies for 3-Year EBITDA Growth Rate. This places Oragenics in the top 6% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.95. Oragenics' value of 72.80% is 387% above this benchmark. Historically, Oragenics' own 3-Year EBITDA Growth Rate has ranged from 1.80 to 72.80 over the past decade. While the company's 10-year median is 31.90 vs. the industry median of 14.95, Oragenics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.95, based on 1,136 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oragenics's current 3-Year EBITDA Growth Rate of 72.80% is 387% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Oragenics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oragenics's current 3-Year EBITDA Growth Rate is 72.80%, which is 128% above median its own 10-year median of 31.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oragenics stock overvalued right now?
Oragenics (OGEN) has a current 3-Year EBITDA Growth Rate of 72.80%. The current 3-Year EBITDA Growth Rate is 72.80%, which is 128% above median its 10-year median of 31.90 and 387% above the Biotechnology industry median of 14.95. Oragenics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Oragenics (OGEN), the current 3-Year EBITDA Growth Rate is 72.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.
30GF Score
Get the complete analysis for OGEN
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OGEN has been successfully added to your 
